Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
SarcoMed Logo
SarcoMed CB Rank
431950
Heat Score
54
SarcoMed develops therapeutic solutions for treating chronic pulmonary inflammation.
Founded
obfuscation
Private Houston, Texas, United States www.sarcomedusa.com/
Biotechnology
Health Care
Therapeutics
Overview

SarcoMed
Heat Score
54

Growth Score
pts
in past quarter
Heat Score 54
-3 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About SarcoMed

CB Rank
431950
SarcoMed develops therapeutic solutions for treating chronic pulmonary inflammation.
Founded
obfuscation
Private Houston, Texas, United States www.sarcomedusa.com/
Biotechnology
Health Care
Therapeutics

Key People

Details

Legal Name SarcoMed USA Inc.
Also Known As SarcoMed USA
Operating Status Active
Company Type For Profit
Founders  Filmon Solomon
About the Company
SarcoMed develops therapeutic solutions for treating chronic pulmonary inflammation. SarcoMed's lead product candidate, SM001, is a recombinant form of human deoxyribonuclease I (DNase I), with a proven mechanism of action and a differentiated clinical profile. SarcoMed was founded in 2017.
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

SM001
SM001 is a modified recombinant human DNase I, formulated for inhalation to address pulmonary sarcoidosis by breaking down extracellular DNA and reducing inflammation.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Employee Profiles 1

Employee Profiles

News
Technology
View Tech Report

Monthly Web Visits

286
167.29%
 in past month

Active Website Tech Count

3SarcoMed is actively using 3 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m and  Cloudflare Blocked.

Total IP

1SarcoMed has 1 registered trademark in the 'Scientific and technological services' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is SarcoMed's headquarters? SarcoMed is located in Houston, Texas, United States.Who are SarcoMed's competitors? Alternatives and possible competitors to SarcoMed may include AstraZeneca, Amgen, and  Vertex Pharmaceuticals.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(64a2f73 1)
|